Quantum-Si News: Single-Molecule Protein Sequencing Platform
Quantum-Si News
Quantum-Si Incorporated released two new articles that rigorously validate their benchtop single-molecule protein sequencing platform, a big step forward for the post-genomic age. These articles demonstrate how the platform can be used for clinical and diagnostic applications like pathogen identification and hemoglobin variation detection.
Protein Analysis Paradigm Change
The Quantum-Si has made protein sequencing as accessible as DNA sequencing. Platinum and Platinum Pro are the first commercial next-generation protein sequencing (NGPS) machines with single-molecule, single-amino-acid precision.
Quantum-Si sequences proteins using real-time kinetic insights and integrated semiconductor devices, unlike mass spectrometry and Edman degradation, which are complicated and slow. Traditional immunoassays ignore proteoforms and PTMs, which determine protein function and disease significance. This method identifies them.
Clinical Hemoglobinopathy Advances
A Stanford laboratory investigation in the Journal of Analytical Chemistry validates the platform. Researchers used Quantum-Si's single-molecule sequencing to find clinically important hemoglobin (Hb) differences in blood samples.
Normal diagnostic methods can struggle to diagnose hemoglobinopathies, red blood cell diseases. The device can analyze individual protein molecules, a resolution not possible in clinical settings. This method may be used in hemoglobinopathy and clinical proteomics research to discover novel variations and understand processes as sequencing coverage rises.
Fast Pathogen/Toxin Detection
The NRL employed it for biosafety and rapid diagnostics. Redesigned by the NRL team, biological sample-to-result data is produced in under 24 hours, a considerable reduction in complex protein analysis turnaround time.
Legacy proteomics requires time-consuming preparation procedures, while this streamlined analytical technique does not. The scientists showed that the platform could recognize long single-domain antibodies, shorter protein toxoids, and proteins in complex combinations. Quantum-Si President and CEO Jeff Hawkins said this result shows the technology's capacity to handle complex situations and environmental issues that existing solutions cannot.
The Platinum Pro Benefit
Without lab space or expertise, the Platinum Pro sequencer is easy to use. Quantum-Si wants single-molecule analysis in “every lab, everywhere” by democratizing proteomics.
Important platform features include:
Single-molecule Resolution: Detects amino acid and isobaric alterations in unprecedented resolution.
Simplified Workflow: The system requires less than three hours of hands-on time for fast-paced labs.
Nanogram Input: The new Library Prep Kit V3 lets researchers draw biological conclusions from 200 ng of protein.
Flexibility: The device enables local and cloud data processing and has a larger touchscreen for easy use.
Kinetics simplify protein sequencing compared to Edman degradation and delve deeper than mass spectrometry to discover amino acid-level changes that are essential for understanding health and illness.
Growth into Drug Development and Beyond
Quantum-Si protein barcoding is revolutionizing pharmaceutical development beyond clinical diagnostics. This method characterizes many protein variations simultaneously, improving screening and therapeutic development throughput.
Pharmaceutical applications for the platform are numerous:
Accelerated Drug Delivery: It simplifies in vivo screening of delivery vehicles including LNPs and AAV capsids, improving discovery program precision.
Comprehensive Variant Analysis: It tracks and characterizes CRISPR and directed evolution-derived protein variants, supporting targeted medication development.
Enhanced Interaction Studies: It studies protein trafficking and interactions in detail, exposing biological pathways essential for quantum drug discovery.
Antibody Characterisation: The approach provides detailed antibody specificity, affinity, and purity, maximizing therapeutic efficacy.
Strategic Vision 2026
These two manuscripts are just the start of Quantum-Si's strategic expansion. CEO Jeff Hawkins said the company wants to offer a strong pipeline of studies by 2026, demonstrating how the technology extends beyond basic research into clinical proteomics.
Quantum-Si allows researchers to study proteins at unprecedented scale by combining quantum biology, chemistry, and AI. Academic research and commercial biomarker identification and disease mechanism analysis are benefiting from this breakthrough.
The Platinum platform, the only commercial benchtop technology for single-molecule protein sequencing, is poised to lead post-genomic discoveries. Single-amino acid resolution on a small, user-friendly device revolutionizes proteomics and puts it in the hands of every scientist.
